Table 3.
Proportion of ever-employed adults with current asthma by asthma drug class and WRA status.
| Drug Class a | WRA (N =2 224 263)b %b (95% CI) |
Possible WRA (N =6 094 064)b %b (95% CI) |
Non-WRA (N = 6 784 072)b %b 95% CI |
WRA vs non-WRA PRc (95% CI) |
Possible WRA vs non-WRA PRc (95% CI) |
|---|---|---|---|---|---|
| Controller | |||||
| Long-acting β-agonist | 28.2 (24.3–32.1) | 23.7 (21.5–26.0) | 21.2 (19.1–23.3) | 1.15 (0.95–1.39) | 1.05 (0.92–1.21) |
| Inhaled corticosteroid | 38.3 (33.8–42.9) | 36.0 (33.2–38.7) | 32.2 (29.6–34.8) | 1.04 (0.89–1.21) | 1.06 (0.95–1.18) |
| Oral corticosteroid | 5.5 (3.8–7.3) | 3.0 (1.8–4.2) | 2.5 (1.7–3.4) | 1.29 (0.83–1.99) | 0.95 (0.62–1.45) |
| Cromolyn/nedocromil | — | — | — | — | — |
| Leukotriene pathway inhibitor | 16.0 (12.7–19.3) | 10.9 (9.4–12.4) | 10.5 (8.7–12.2) | 1.59 (1.22–2.07) | 1.22 (0.97–1.52) |
| Methylxanthine | 1.8 (0.8–2.8) | 1.1 (0.7–1.6) | 0.3 (0.2–0.5) | 4.76 (2.06–11.0) | 2.85 (1.55–5.23) |
| Anti-cholinergic | 9.9 (6.3–13.4) | 5.3 (4.3–6.3) | 3.5 (2.8–4.2) | 1.80 (1.05–3.06) | 1.18 (0.90–1.56) |
| Rescue | |||||
| Short-acting β-agonist | 61.2 (56.6–65.9) | 57.5 (54.5–60.4) | 50.2 (47.2–53.2) | 0.99 (0.88–1.10) | 1.02 (0.95–1.10) |
a
Medications used in 3 months preceding the survey interview.
b
Results presented as weighted annual average.
c
Consists of eight models where the outcome variables were drug class and the predictor variable was WRA status, adjusted for age, sex, race/ethnicity, income, health insurance, current employment status, chronic obstructive pulmonary disease (COPD), and adverse asthma outcomes.
CI, confidence interval; PR, prevalence ratio; WRA, work-related asthma; Bold text indicates significance; “–” indicates relative standard error >30%, estimate not reportable.